Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Abroad (travel likely)RecruitingPHASE2
Conditions
Neuroendocrine Tumors · Well-Differentiated Neuroendocrine Carcinoma · High Grade Neuroendocrine Carcinoma, Any Site
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, San Francisco, San Francisco, California, United States
Contact: Principal Investigator (Emily Bergsland, MD)
Study leads
Emily Bergsland, MD
Principal Investigator
University of California, San Francisco